繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

X4 Pharmaceuticals宣布战略重组,裁员50%,预计每年节省1300万美元的成本

2025-09-17 19:12

  • Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M
  • John Volpone appointed Chief Operating Officer, in addition to his current role as President
  • Dr. Adam Craig, Executive Chairman, to have oversight over clinical development

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。